Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Short term Debt (2017 - 2025)

United Therapeutics (UTHR) has disclosed Short term Debt for 6 consecutive years, with $200.0 million as the latest value for Q1 2025.

  • Quarterly Short term Debt fell 50.0% to $200.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $200.0 million through Mar 2025, down 50.0% year-over-year, with the annual reading at $300.0 million for FY2024, 25.0% down from the prior year.
  • Short term Debt hit $200.0 million in Q1 2025 for United Therapeutics, down from $300.0 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $400.0 million in Q4 2023 to a low of $200.0 million in Q1 2025.
  • Historically, Short term Debt has averaged $342.9 million across 3 years, with a median of $400.0 million in 2023.
  • Biggest five-year swings in Short term Debt: soared 33.33% in 2024 and later crashed 50.0% in 2025.
  • Year by year, Short term Debt stood at $400.0 million in 2023, then dropped by 25.0% to $300.0 million in 2024, then crashed by 33.33% to $200.0 million in 2025.
  • Business Quant data shows Short term Debt for UTHR at $200.0 million in Q1 2025, $300.0 million in Q4 2024, and $400.0 million in Q3 2024.